[ad_1]
dublin, February 22, 2024 /PRNewswire/ — Theravance Biopharma, Inc. (Nasdaq: TBPH) will participate in a CNS company panel discussion at TD Cowen’s 44th Annual Healthcare Conference Boston, Massachusetts exist Tuesday, March 5 exist 10:30 a.m. ET (7:30 a.m. Pacific time/3:30pm GMT). Members of Theravance Biopharma’s senior management will host one-on-one meetings at the conference.
The event’s webcast can be accessed by visiting Events & Presentations in the Investors section of Theravance.com. A replay of the webcast will be archived on the Company’s website for 30 days.
About Theravance Biopharmaceuticals
Theravance Biopharma, Inc. is focused on delivering impactful medicines® in people’s lives. To achieve its goals, Theravance Biopharma leveraged decades of expertise to develop FDA-approved YUPELRI® (revefenacin) inhalation solution is suitable for maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Amproxetine, a late-stage investigational norepinephrine reuptake inhibitor being developed for the treatment of symptomatic neurogenic orthostatic hypotension, has the potential to be the first of its kind to effectively treat a range of major symptoms in patients with multisymptomatic atrophy. A therapy. The company is committed to creating/driving shareholder value.
For more information, please visit www.theravance.com.
SeraVance Biopharmaceuticals®treat® and the cross/star logo are registered trademarks of Theravance Biopharma, Inc. in the United States and certain other countries.
Jupeli® is a registered trademark of Mylan Specialty LP, a Viatris company. The trademarks, trade names or service marks of other companies appearing in this release are the property of their respective owners.
touch:
Investor.relations@theravance.com
650-808-4045
View original content to download multimedia: https://www.prnewswire.com/news-releases/theravance-biopharma-to-participate-in-an-upcoming-investor-conference-302068341.html
SOURCE Theravance Biopharma, Inc.
[ad_2]
Source link